Latest Csl Ltd (CMXHF) Headlines
Between 2012-2016, the Global Telecom Industry to Witness Double Digit Growth in the LTE and HSPA Subscriptions and Will Cross 4 Billion By 2016
M2 - Thu Mar 06, 11:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkshnb/global_voice_over) has announced the addition of the "Global Voice over Mobile Broadband (VoMBB) Market 2012-2016" report to their offering. Voice over Mobile Broadband, or VoMBB, has been recently gaining traction in the Global Telecom industry and is unanimously expected to generate huge revenue for telecom network operators in the coming years. Conceptually, VoMBB is about encompassing carrier-grade voice calls over LTE, Wi-Fi and HSPA/HSPA networks. The telecom operators mentioned in the report include A-1 Telecom Inc., AT&T Inc., Axis Telecom Inc., Bell Mobility Inc., Bharti Airtel Ltd., Bouygues Telecom, Celcom Axiata Berhad, Cellular South Inc., Chess Ltd., China Mobile Ltd., CSL Ltd., Chunghwa Telecom Co. Ltd., Clearwire Corp., Cosmote Mobile Telecommunications SA, CSL Ltd., DNA Oy, Deutsche Telekom AG, Emirates Integrated Telecommunications Company PJSC, Emirates Telecommunications Corp. (Etisalat), E-Plus Mobilfunk GmbH & Co. KG, EE Ltd., Etihad Etisalat Co.(Mobily), MobiNil Telecommunication S.A.E., Hutchison 3G, KT Corp., Kcell, KPN B.V. , KT Corp., Magyar Telecom B.V., Megafon S.A., Mobitel, MetroPCS Inc., Mobile TeleSystems OJSC, Netcom, NTT DoCoMo Inc., Mobistar S.A., M-Tel, Vodafone Group plc, VIPnet d.o.o, VIP Mobile d.o.o., Smart Communications Inc., Saudi Telecom Co., SK Telecom Co., Ltd., Si.mobil d.d., SFR SA, Swisscom AG, StarHub Ltd., Qatar Telecom Q.S.C, Rogers Communications Inc., P4 Sp. z o.o., Partner Communications Co Ltd., Orange S.A., Telefonica Europe plc, LG Uplus Corp., Megafon OJSC, Orange S.A., StarHub Ltd., Vodafone Group plc, SaskTel International Consulting Inc., Sprint Nextel Corp., Tele2 AB, Telekom Slovenije D.D., TeliaSonera AB, Turkcell Iletisim Hizmetleri A.S., T-Mobile International AG & Co. KG, Telecomunicacoes Moveis Nacionais S.A., Telecom Italia Mobile S.p.A., Teliasonera AB , Telus Corp., Telstra Corp Ltd., Telenor ASA, Telekom Austria AG, TDC A/S, Tata DoCoMo Ltd., Total Access Communication Public Company Ltd. (DTAC), United States Cellular Corp., Verizon Communications Inc., and Wind Mobile. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Voice over Mobile Broadband market is the refarming of 2G spectrum. To maximize and monetize user experience, the telecom operators will be contemplating the advantage of refarming the spectrum occupied by the legacy networks; this would help use the efficient spectrum to provide the high-end data applications along with voice. The refarming will enable the telecom operators to enhance the quality and capacity of their networks with spending exorbitantly in buying the spectrum. According to the report, one of the main factors driving the market is the increasing requirement for traffic offloading. As long as mobile operators have visibility into the quality of the subscribers' Wi-Fi connection (through a hotspot, a residential access point, or an enterprise network), they can decide which voice traffic can be routed through Wi-Fi while preserving or improving the quality of experience. For more information visit http://www.researchandmarkets.com/research/kk...voice_over About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the International Intravenous Immunoglobulin (IVIg) Market
M2 - Tue Feb 25, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/m8bpfg/intravenous) has announced the addition of the "Concise Analysis of the International Intravenous Immunoglobulin (IVIg) Market" report to their offering. This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 27 companies including many key and niche players such as: - Baxter International Inc. - Beijing Tiantan Biological Products Co. Ltd. - Bharat Serums and Vaccines Ltd. - Biotest AG - China Biologic Products Inc. - Guizhou Taibang Biological Products Co. Ltd. - CSL Limited - CSL Behring - Grifols S.A - Huanlan Biological Engineering Inc. - Kedrion S.p.A. - LFB Group - Octapharma AG - OMRIX Biopharmaceuticals Ltd. - Shanghai RAAS Blood Products Co. Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Plasma Proteins - An Overview 3. Immunoglobulins - An Overview 4. Therapy Overview 5. Regulatory Approvals 6. Product Innovations/Introductions 7. Recent Industry Activity 8. Focus On Select Players 9. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 27 (including Divisions/Subsidiaries - 34) - The United States (9) - Canada (2) - Japan (2) - Europe (9) - France (2) - Germany (1) - The United Kingdom (1) - Italy (1) - Spain (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (11) - Middle-East (1) For more information visit http://www.researchandmarkets.com/research/m8...ntravenous
Periodontitis - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 21, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h4fxc9/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H2 2013" report to their offering. 'Periodontitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Periodontitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Periodontitis - Therapeutics Assessment Drug Profiles trafermin - Drug Profile simvastatin - Drug Profile Asterias - Drug Profile Stem Cell Therapy For Osteoporosis And Bone Regeneration - Drug Profile C5a Receptor Antagonist - Drug Profile OPM-3023 - Drug Profile Drug For Biofilms - Drug Profile ANR Program for Periodontitis - Drug Profile POD CRC-OHS - Drug Profile Antibacterial Agent - Drug Profile Sharon-3000 - Drug Profile Drug For Periodontal Disease - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Aphios Corporation Kaken Pharmaceutical Co., Ltd. CSL Limited NeoStem, Inc. Onepharm Research and Development GmbH Canopus BioPharma Incorporated Ensoltek Co., Ltd. OTR3 For more information visit http://www.researchandmarkets.com/research/h4...iodontitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CNSI Selected by Two Maryland State Agencies for Separate IT Development and Support Contracts
PR Newswire - Tue Jan 21, 10:00AM CST
CNSI today announced it has been selected by the Maryland State Highway Authority (SHA) to provide Application Portfolio Business Services. As part of the task order under the State of Maryland - Consulting and Technical Services (CATS+) Master Contract, CNSI will continue to provide SHA's business applications development and maintenance for the next five years. CNSI also has been selected by the Maryland Port Administration (MPA) to continue providing programming and database management support services for an additional five years.
Market Research: Hereditary Angioedema (HAE) - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/x8rgxd/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H2 2013" report to their offering. 'Hereditary Angioedema (HAE) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE). Scope - A snapshot of the global therapeutic scenario for Hereditary Angioedema (HAE). - A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Isis Pharmaceuticals, Inc. Pharming Group N.V. Dyax Corp. ViroPharma Incorporated BioCryst Pharmaceuticals, Inc. CSL Limited iBio, Inc. For more information visit http://www.researchandmarkets.com/research/x8rgxd/hereditary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sustainable Development And Responsible Business Practice Aren't Just Words At The CSL Group Of Companies
PR Newswire - Tue Dec 03, 1:00PM CST
CSL Behring's parent company CSL Limited (ASX:CSL) reaffirms the companies' commitment to responsible business practice and sustainable development in its new corporate responsibility report - Our Corporate Responsibility 2013. The report details CSL's performance across key corporate responsibility priority areas for the period July 1, 2012 through June 30, 2013.
Research Report: Cystic Fibrosis - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/wfwrck/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cystic Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Genzyme Corporation Johnson & Johnson Boehringer Ingelheim GmbH GlaxoSmithKline plc Gilead Sciences, Inc. Vectura Group plc Novartis AG Axcan Pharma Inc. Chiesi Farmaceutici SpA Pfizer Inc. Vertex Pharmaceuticals Incorporated Zambon Group S.p.A. Optimer Pharmaceuticals, Inc. PARI Pharma GmbH Hollis-Eden Pharmaceuticals, Inc. Pharmaxis Ltd. CSL Limited Protalix BioTherapeutics, Inc. Lipoxen PLC Galapagos NV Kamada Ltd. Proteo, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/wf...c_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Emphysema Clinical Trials Review Report, H2 2013
M2 - Mon Oct 21, 11:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdkfpg/emphysema_global) has announced the addition of the "Emphysema Global Clinical Trials Review, H2, 2013" report to their offering. Emphysema Global Clinical Trials Review, H2, 2013" provides data on the Emphysema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Emphysema. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Emphysema. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned - Aeris Therapeutics, Inc. - AstraZeneca PLC - Bayer AG - CSL Limited - Dainippon Sumitomo Pharma Co., Ltd. - Deep Breeze Ltd. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Grifols, S.A. - Uptake Medical Corporation For more information visit http://www.researchandmarkets.com/research/jd...ema_global
Global Hemophilia Clinical Trials Review, H2 2013 Analysis
M2 - Tue Oct 15, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc4lwr/hemophilia_global) has announced the addition of the "Hemophilia Global Clinical Trials Review, H2, 2013" report to their offering. Hemophilia Global Clinical Trials Review, H2, 2013" provides data on the Hemophilia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemophilia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hemophilia. Reasons to buy: - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Hemophilia Therapeutics Clinical Trials - Novo Nordisk A/S - Pfizer Inc. - Bayer AG - Baxter International Inc. - Baxter Healthcare Corporation - Octapharma AG - CSL Limited - Biogen Idec Inc. - CSL Behring LLC - Prolor Biotech, Inc. - Grifols, S.A. - rEVO Biologics - UMC Utrecht Holding BV - Green Cross Corporation - Recoly N.V. . - LFB Biotechnologies, S.A.S - Cangene Corporation - Chugai Pharmaceutical Co., Ltd. - Octapharma Limited - Inspiration BioPharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/cc...lia_global
CSL and Plasma Protein Therapeutics Association Agree to Pay $64 Million To Settle Plasma-Derivative Protein Therapies Antitrust Case
Business Wire - Tue Oct 08, 8:51AM CDT
CSL Limited, CSL Behring LLC, CSL Plasma, Inc. (collectively, "CSL"), and the Plasma Protein Therapeutics Association ("PPTA") have agreed to pay $64 million dollars to settle a lawsuit brought by the University of Utah Hospital and other health care providers alleging that CSL, the PPTA, and Baxter, Inc., agreed between 2003-2009 to restrict the supply of immunoglobulin and albumin, and thereby increase the prices of those therapies, according to attorneys at Cohen Milstein Sellers & Toll PLLC and Williams, Montgomery & John Ltd.
H1N1 Vaccines - Global Strategic Business Report
M2 - Mon Oct 07, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zwdhqn/h1n1_vaccines#summary) has announced the addition of the "H1N1 Vaccines - Global Strategic Business Report" report to their offering. This report analyzes the Global market for H1N1 Vaccines in US$ Million. The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. The report profiles 29 companies including many key and niche players such as: - Abbott Laboratories - Baxter International, Inc. - CPL Biologicals Pvt. Ltd. - CSL Limited - bioCSL - GlaxoSmithKline Plc - MedImmune, LLC - Novartis AG - Sanofi Pasteur - SA - Sinovac Biotech Ltd. - Zydus Cadila. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For more information visit http://www.researchandmarkets.com/research/zw...es#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ZTE Activates Hong Kong's First 300Mbps-Capable 4G Network for CSL
Business Wire - Tue Sep 10, 3:58AM CDT
ZTE Corporation ("ZTE") (H share stock code: 0763.HK / A share stock code: 000063.SZ), a publicly-listed global provider of telecommunications equipment, network solutions and mobile devices, today helped CSL Limited complete a demonstration of Hong Kong's first 300Mbps-ready 4G network, paving the way for wider-scale commercial deployment of next-generation mobile services to consumers and business customers.
Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
World LTE Market - Database: Markets at June 2013 & Forecasts to 2017 Featuring More than 70 LTE Operators
M2 - Fri Sep 06, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kl8hx8/world_lte_market) has announced the addition of the "World LTE Market - Database: Markets at June 2013 & Forecasts to 2017" directory to their offering. This half-yearly updated LTE database is an excellent tool to benchmark the different markets on a country level - 42 countries and 6 zones - and to assess business opportunities - more than 70 LTE operator sheets with current and upcoming deployments. This solution is also a gain of time - spectrum issues, technologies deployed, revenue & subscriber data & forecasts up to 2017 brought altogether in one database. One update in December 2013 is included within the license for this database. This Database is part of our ongoing monitoring LTE Watch that includes: - Half-yearly updated datasets - Half-yearly updated status reports - Bimonthly market insights - Direct access to lead LTE analysts Companies Mentioned: Austria - Mobilkom - Orange - T-Mobile - Hutchison 3G Argentina - Telefonica Argentina - Telecom Personal Australia - Telstra - NBN Co - Vividwireless - Optus - Vodafone Hutchison Bahrain - Zain - Batelco - Viva Belgium - Belgacom - Clearwire - Mobistar - Telenet Brazil - Vivo - Oi - Sky - America Movil Canada - Bell Mobility - Rogers Wireless - Telus Chile - Entel PCS China - China Mobile - China Unicom - China Telecom Czech Republic - T-Mobile - Telefonica O2 Denmark - Telenor - TDC - Hi3G - Telia Finland - DNA - Elisa - TeliaSonera France - Bouygues Telecom - Orange - SFR Germany - E-Plus - O2 - T-Mobile - Vodafone Hungary - Telenor - Magyar Telekom - Vodafone Hungary Hong Kong - Smartone Vodafone - CSL Limited - PCCW - 3 - China Mobile Hong Kong India - Reliance Industries - Augere - Aircel - Bharti Airtel Indonesia - Telkomsel - Indosat Ireland - 3 Ireland - Imagine Communications Group Italia - 3 - TIM - Vodafone - Wind Japan - eMobile - KDDI - NTT/DoCoMo - Softbank Mobile Malaysia - Maxis - Packet One Networks Mexico - MVS Comunicaciones - Telefonica - Telcel (America Movil) Netherlands - Tele2 - KPN Netherlands Norway - Telenor Mobile - TeliaSonera New Zealand - Telecom New-Zealand Philippines - Piltel - Smart Communications (PLDT) - Globe Poland - Aero2 - Play (Polkomtel) - Networks! (T-Mobile&Orange) - Cyfrowy Polsat Portugal - TMN - Vodafone Portugal - Optimus Russia - MegaFon - Yota - Rostelecom - MTS - VimpelCom - Tele2 Saudi Arabia - Saoudi Telecom Company (STC) - Etisalat - Zain Saudi Arabia Singapore - Singtel - Starhub - MobileOne M1 South Korea - KT - LG Telecom - SK Telecom Spain - Orange - Telefonica - Vodafone - Clearwire - Xfera Sweden - Net4mobility - Telenor Mobile - Hi3G - TeliaSonera Switzerland - Swisscom Taiwan - Chunghwa Turkey - Turkcell UAE - DU - Etisalat UK - 3 - Virgin Mobile - O2 - UK Broadband - Orange T-Mobile - Vodafone USA - AT&T Mobility - Century Tel - Clearwire - Cox - Comcast - Time Warner Cable - Sprint Nextel - US Cellular - MetroPCS - Leap Wireless - T-Mobile - Verizon - Light Squared Uzbekistan - MTS - Ucell (TeliaSonera) Vietnam - VNPT - Indochina Telecom - Viettel For more information visit http://www.researchandmarkets.com/research/kl...lte_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Periodontal Disease - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Those in the Dental Field
M2 - Wed Sep 04, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sp3kl2/periodontal) has announced the addition of the "Periodontal Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Periodontal Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontal Disease, complete with latest updates, and special features on late-stage and discontinued projects. Periodontal Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Periodontal Disease. - A review of the Periodontal Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontal Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aphios Corporation - Biomedical Development Corporation - CSL Limited - Canopus BioPharma Incorporated - Ensoltek Co., Ltd. - Kaken Pharmaceutical Co.,Ltd. - NeoStem, Inc. - Onepharm Research and Development GmbH - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/sp...eriodontal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Acute Coronary Syndrome - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t22wlp/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H2 2013" report to their offering. 'Acute Coronary Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Scope - A snapshot of the global therapeutic scenario for Acute Coronary Syndrome. - A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. AstraZeneca PLC GlaxoSmithKline plc Pfizer Inc. Bayer AG Ligand Pharmaceuticals Incorporated Medicure Inc. Arena Pharmaceuticals, Inc. CSL Limited LG Life Sciences, Ltd Auspex Pharmaceuticals Viron Therapeutics, Inc. Regado Biosciences. Cerenis Therapeutics SA Lacer, S.A. Lee's Pharmaceutical Holdings Limited Ampio Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/t2...e_coronary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report: 2013 Profiles 27 Players including Key and Niche Players
M2 - Tue Sep 03, 9:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjhhwq/intravenous#summary) has announced the addition of the "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 27 companies including many key and niche players such as: - Baxter International Inc. - Beijing Tiantan Biological Products Co. Ltd. - Bharat Serums and Vaccines Ltd. - Biotest AG - China Biologic Products Inc. - Guizhou Taibang Biological Products Co. Ltd. - CSL Limited - CSL Behring - Grifols S.A - Huanlan Biological Engineering Inc. - Kedrion S.p.A. - LFB Group - Octapharma AG - OMRIX Biopharmaceuticals Ltd. - Shanghai RAAS Blood Products Co. Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered: Normal 0 false false false MicrosoftInternetExplorer4 I. Introduction, Methodology & Product Definitions Ii. Executive Summary 1. Industry Overview 2. Plasma Proteins - An Overview 3. Immunoglobulins - An Overview 4. Therapy Overview 5. Regulatory Approvals 6. Product Innovations/Introductions 7. Recent Industry Activity 8. Focus On Select Players 9. Global Market Perspective Iii. Market Iv. Competitive Landscape For more information visit http://www.researchandmarkets.com/research/hj...us#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Atherosclerosis - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n99vdc/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2013" report to their offering. 'Atherosclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Atherosclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Atherosclerosis. Scope - A snapshot of the global therapeutic scenario for Atherosclerosis. - A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Atherosclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Isis Pharmaceuticals, Inc. Daiichi Sankyo Company, Ltd Merck & Co., Inc. Novartis AG Dong-A Pharmaceutical Co., Ltd. Dr. Reddy's Laboratories Limited Zydus Cadila Healthcare Limited Bayer AG Genfit PROLOR Biotech, Inc. CSL Limited Yuhan Corporation Anagen Therapeutics, Inc. Cytos Biotechnology AG Pronova BioPharma ASA AFFiRiS AG CIMAB S.A. and many more..... For more information visit http://www.researchandmarkets.com/research/n9...osclerosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Periodontitis - Pipeline Review, H1 2013
M2 - Wed Jul 17, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2qfrh/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H1 2013" report to their offering. 'Periodontitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Periodontitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis prod
Between 2012-2016, the Global Telecom Industry to Witness Double Digit Growth in the LTE and HSPA Subscriptions and Will Cross 4 Billion By 2016
M2 - Thu Mar 06, 11:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkshnb/global_voice_over) has announced the addition of the "Global Voice over Mobile Broadband (VoMBB) Market 2012-2016" report to their offering. Voice over Mobile Broadband, or VoMBB, has been recently gaining traction in the Global Telecom industry and is unanimously expected to generate huge revenue for telecom network operators in the coming years. Conceptually, VoMBB is about encompassing carrier-grade voice calls over LTE, Wi-Fi and HSPA/HSPA networks. The telecom operators mentioned in the report include A-1 Telecom Inc., AT&T Inc., Axis Telecom Inc., Bell Mobility Inc., Bharti Airtel Ltd., Bouygues Telecom, Celcom Axiata Berhad, Cellular South Inc., Chess Ltd., China Mobile Ltd., CSL Ltd., Chunghwa Telecom Co. Ltd., Clearwire Corp., Cosmote Mobile Telecommunications SA, CSL Ltd., DNA Oy, Deutsche Telekom AG, Emirates Integrated Telecommunications Company PJSC, Emirates Telecommunications Corp. (Etisalat), E-Plus Mobilfunk GmbH & Co. KG, EE Ltd., Etihad Etisalat Co.(Mobily), MobiNil Telecommunication S.A.E., Hutchison 3G, KT Corp., Kcell, KPN B.V. , KT Corp., Magyar Telecom B.V., Megafon S.A., Mobitel, MetroPCS Inc., Mobile TeleSystems OJSC, Netcom, NTT DoCoMo Inc., Mobistar S.A., M-Tel, Vodafone Group plc, VIPnet d.o.o, VIP Mobile d.o.o., Smart Communications Inc., Saudi Telecom Co., SK Telecom Co., Ltd., Si.mobil d.d., SFR SA, Swisscom AG, StarHub Ltd., Qatar Telecom Q.S.C, Rogers Communications Inc., P4 Sp. z o.o., Partner Communications Co Ltd., Orange S.A., Telefonica Europe plc, LG Uplus Corp., Megafon OJSC, Orange S.A., StarHub Ltd., Vodafone Group plc, SaskTel International Consulting Inc., Sprint Nextel Corp., Tele2 AB, Telekom Slovenije D.D., TeliaSonera AB, Turkcell Iletisim Hizmetleri A.S., T-Mobile International AG & Co. KG, Telecomunicacoes Moveis Nacionais S.A., Telecom Italia Mobile S.p.A., Teliasonera AB , Telus Corp., Telstra Corp Ltd., Telenor ASA, Telekom Austria AG, TDC A/S, Tata DoCoMo Ltd., Total Access Communication Public Company Ltd. (DTAC), United States Cellular Corp., Verizon Communications Inc., and Wind Mobile. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Voice over Mobile Broadband market is the refarming of 2G spectrum. To maximize and monetize user experience, the telecom operators will be contemplating the advantage of refarming the spectrum occupied by the legacy networks; this would help use the efficient spectrum to provide the high-end data applications along with voice. The refarming will enable the telecom operators to enhance the quality and capacity of their networks with spending exorbitantly in buying the spectrum. According to the report, one of the main factors driving the market is the increasing requirement for traffic offloading. As long as mobile operators have visibility into the quality of the subscribers' Wi-Fi connection (through a hotspot, a residential access point, or an enterprise network), they can decide which voice traffic can be routed through Wi-Fi while preserving or improving the quality of experience. For more information visit http://www.researchandmarkets.com/research/kk...voice_over About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the International Intravenous Immunoglobulin (IVIg) Market
M2 - Tue Feb 25, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/m8bpfg/intravenous) has announced the addition of the "Concise Analysis of the International Intravenous Immunoglobulin (IVIg) Market" report to their offering. This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 27 companies including many key and niche players such as: - Baxter International Inc. - Beijing Tiantan Biological Products Co. Ltd. - Bharat Serums and Vaccines Ltd. - Biotest AG - China Biologic Products Inc. - Guizhou Taibang Biological Products Co. Ltd. - CSL Limited - CSL Behring - Grifols S.A - Huanlan Biological Engineering Inc. - Kedrion S.p.A. - LFB Group - Octapharma AG - OMRIX Biopharmaceuticals Ltd. - Shanghai RAAS Blood Products Co. Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Plasma Proteins - An Overview 3. Immunoglobulins - An Overview 4. Therapy Overview 5. Regulatory Approvals 6. Product Innovations/Introductions 7. Recent Industry Activity 8. Focus On Select Players 9. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 27 (including Divisions/Subsidiaries - 34) - The United States (9) - Canada (2) - Japan (2) - Europe (9) - France (2) - Germany (1) - The United Kingdom (1) - Italy (1) - Spain (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (11) - Middle-East (1) For more information visit http://www.researchandmarkets.com/research/m8...ntravenous
Periodontitis - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 21, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h4fxc9/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H2 2013" report to their offering. 'Periodontitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Periodontitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Periodontitis - Therapeutics Assessment Drug Profiles trafermin - Drug Profile simvastatin - Drug Profile Asterias - Drug Profile Stem Cell Therapy For Osteoporosis And Bone Regeneration - Drug Profile C5a Receptor Antagonist - Drug Profile OPM-3023 - Drug Profile Drug For Biofilms - Drug Profile ANR Program for Periodontitis - Drug Profile POD CRC-OHS - Drug Profile Antibacterial Agent - Drug Profile Sharon-3000 - Drug Profile Drug For Periodontal Disease - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Aphios Corporation Kaken Pharmaceutical Co., Ltd. CSL Limited NeoStem, Inc. Onepharm Research and Development GmbH Canopus BioPharma Incorporated Ensoltek Co., Ltd. OTR3 For more information visit http://www.researchandmarkets.com/research/h4...iodontitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CNSI Selected by Two Maryland State Agencies for Separate IT Development and Support Contracts
PR Newswire - Tue Jan 21, 10:00AM CST
CNSI today announced it has been selected by the Maryland State Highway Authority (SHA) to provide Application Portfolio Business Services. As part of the task order under the State of Maryland - Consulting and Technical Services (CATS+) Master Contract, CNSI will continue to provide SHA's business applications development and maintenance for the next five years. CNSI also has been selected by the Maryland Port Administration (MPA) to continue providing programming and database management support services for an additional five years.
Market Research: Hereditary Angioedema (HAE) - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/x8rgxd/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H2 2013" report to their offering. 'Hereditary Angioedema (HAE) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE). Scope - A snapshot of the global therapeutic scenario for Hereditary Angioedema (HAE). - A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Isis Pharmaceuticals, Inc. Pharming Group N.V. Dyax Corp. ViroPharma Incorporated BioCryst Pharmaceuticals, Inc. CSL Limited iBio, Inc. For more information visit http://www.researchandmarkets.com/research/x8rgxd/hereditary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sustainable Development And Responsible Business Practice Aren't Just Words At The CSL Group Of Companies
PR Newswire - Tue Dec 03, 1:00PM CST
CSL Behring's parent company CSL Limited (ASX:CSL) reaffirms the companies' commitment to responsible business practice and sustainable development in its new corporate responsibility report - Our Corporate Responsibility 2013. The report details CSL's performance across key corporate responsibility priority areas for the period July 1, 2012 through June 30, 2013.
Research Report: Cystic Fibrosis - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/wfwrck/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cystic Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Genzyme Corporation Johnson & Johnson Boehringer Ingelheim GmbH GlaxoSmithKline plc Gilead Sciences, Inc. Vectura Group plc Novartis AG Axcan Pharma Inc. Chiesi Farmaceutici SpA Pfizer Inc. Vertex Pharmaceuticals Incorporated Zambon Group S.p.A. Optimer Pharmaceuticals, Inc. PARI Pharma GmbH Hollis-Eden Pharmaceuticals, Inc. Pharmaxis Ltd. CSL Limited Protalix BioTherapeutics, Inc. Lipoxen PLC Galapagos NV Kamada Ltd. Proteo, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/wf...c_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Emphysema Clinical Trials Review Report, H2 2013
M2 - Mon Oct 21, 11:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdkfpg/emphysema_global) has announced the addition of the "Emphysema Global Clinical Trials Review, H2, 2013" report to their offering. Emphysema Global Clinical Trials Review, H2, 2013" provides data on the Emphysema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Emphysema. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Emphysema. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned - Aeris Therapeutics, Inc. - AstraZeneca PLC - Bayer AG - CSL Limited - Dainippon Sumitomo Pharma Co., Ltd. - Deep Breeze Ltd. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Grifols, S.A. - Uptake Medical Corporation For more information visit http://www.researchandmarkets.com/research/jd...ema_global
Global Hemophilia Clinical Trials Review, H2 2013 Analysis
M2 - Tue Oct 15, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc4lwr/hemophilia_global) has announced the addition of the "Hemophilia Global Clinical Trials Review, H2, 2013" report to their offering. Hemophilia Global Clinical Trials Review, H2, 2013" provides data on the Hemophilia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemophilia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hemophilia. Reasons to buy: - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Hemophilia Therapeutics Clinical Trials - Novo Nordisk A/S - Pfizer Inc. - Bayer AG - Baxter International Inc. - Baxter Healthcare Corporation - Octapharma AG - CSL Limited - Biogen Idec Inc. - CSL Behring LLC - Prolor Biotech, Inc. - Grifols, S.A. - rEVO Biologics - UMC Utrecht Holding BV - Green Cross Corporation - Recoly N.V. . - LFB Biotechnologies, S.A.S - Cangene Corporation - Chugai Pharmaceutical Co., Ltd. - Octapharma Limited - Inspiration BioPharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/cc...lia_global
CSL and Plasma Protein Therapeutics Association Agree to Pay $64 Million To Settle Plasma-Derivative Protein Therapies Antitrust Case
Business Wire - Tue Oct 08, 8:51AM CDT
CSL Limited, CSL Behring LLC, CSL Plasma, Inc. (collectively, "CSL"), and the Plasma Protein Therapeutics Association ("PPTA") have agreed to pay $64 million dollars to settle a lawsuit brought by the University of Utah Hospital and other health care providers alleging that CSL, the PPTA, and Baxter, Inc., agreed between 2003-2009 to restrict the supply of immunoglobulin and albumin, and thereby increase the prices of those therapies, according to attorneys at Cohen Milstein Sellers & Toll PLLC and Williams, Montgomery & John Ltd.
H1N1 Vaccines - Global Strategic Business Report
M2 - Mon Oct 07, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zwdhqn/h1n1_vaccines#summary) has announced the addition of the "H1N1 Vaccines - Global Strategic Business Report" report to their offering. This report analyzes the Global market for H1N1 Vaccines in US$ Million. The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. The report profiles 29 companies including many key and niche players such as: - Abbott Laboratories - Baxter International, Inc. - CPL Biologicals Pvt. Ltd. - CSL Limited - bioCSL - GlaxoSmithKline Plc - MedImmune, LLC - Novartis AG - Sanofi Pasteur - SA - Sinovac Biotech Ltd. - Zydus Cadila. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For more information visit http://www.researchandmarkets.com/research/zw...es#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ZTE Activates Hong Kong's First 300Mbps-Capable 4G Network for CSL
Business Wire - Tue Sep 10, 3:58AM CDT
ZTE Corporation ("ZTE") (H share stock code: 0763.HK / A share stock code: 000063.SZ), a publicly-listed global provider of telecommunications equipment, network solutions and mobile devices, today helped CSL Limited complete a demonstration of Hong Kong's first 300Mbps-ready 4G network, paving the way for wider-scale commercial deployment of next-generation mobile services to consumers and business customers.
Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
World LTE Market - Database: Markets at June 2013 & Forecasts to 2017 Featuring More than 70 LTE Operators
M2 - Fri Sep 06, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kl8hx8/world_lte_market) has announced the addition of the "World LTE Market - Database: Markets at June 2013 & Forecasts to 2017" directory to their offering. This half-yearly updated LTE database is an excellent tool to benchmark the different markets on a country level - 42 countries and 6 zones - and to assess business opportunities - more than 70 LTE operator sheets with current and upcoming deployments. This solution is also a gain of time - spectrum issues, technologies deployed, revenue & subscriber data & forecasts up to 2017 brought altogether in one database. One update in December 2013 is included within the license for this database. This Database is part of our ongoing monitoring LTE Watch that includes: - Half-yearly updated datasets - Half-yearly updated status reports - Bimonthly market insights - Direct access to lead LTE analysts Companies Mentioned: Austria - Mobilkom - Orange - T-Mobile - Hutchison 3G Argentina - Telefonica Argentina - Telecom Personal Australia - Telstra - NBN Co - Vividwireless - Optus - Vodafone Hutchison Bahrain - Zain - Batelco - Viva Belgium - Belgacom - Clearwire - Mobistar - Telenet Brazil - Vivo - Oi - Sky - America Movil Canada - Bell Mobility - Rogers Wireless - Telus Chile - Entel PCS China - China Mobile - China Unicom - China Telecom Czech Republic - T-Mobile - Telefonica O2 Denmark - Telenor - TDC - Hi3G - Telia Finland - DNA - Elisa - TeliaSonera France - Bouygues Telecom - Orange - SFR Germany - E-Plus - O2 - T-Mobile - Vodafone Hungary - Telenor - Magyar Telekom - Vodafone Hungary Hong Kong - Smartone Vodafone - CSL Limited - PCCW - 3 - China Mobile Hong Kong India - Reliance Industries - Augere - Aircel - Bharti Airtel Indonesia - Telkomsel - Indosat Ireland - 3 Ireland - Imagine Communications Group Italia - 3 - TIM - Vodafone - Wind Japan - eMobile - KDDI - NTT/DoCoMo - Softbank Mobile Malaysia - Maxis - Packet One Networks Mexico - MVS Comunicaciones - Telefonica - Telcel (America Movil) Netherlands - Tele2 - KPN Netherlands Norway - Telenor Mobile - TeliaSonera New Zealand - Telecom New-Zealand Philippines - Piltel - Smart Communications (PLDT) - Globe Poland - Aero2 - Play (Polkomtel) - Networks! (T-Mobile&Orange) - Cyfrowy Polsat Portugal - TMN - Vodafone Portugal - Optimus Russia - MegaFon - Yota - Rostelecom - MTS - VimpelCom - Tele2 Saudi Arabia - Saoudi Telecom Company (STC) - Etisalat - Zain Saudi Arabia Singapore - Singtel - Starhub - MobileOne M1 South Korea - KT - LG Telecom - SK Telecom Spain - Orange - Telefonica - Vodafone - Clearwire - Xfera Sweden - Net4mobility - Telenor Mobile - Hi3G - TeliaSonera Switzerland - Swisscom Taiwan - Chunghwa Turkey - Turkcell UAE - DU - Etisalat UK - 3 - Virgin Mobile - O2 - UK Broadband - Orange T-Mobile - Vodafone USA - AT&T Mobility - Century Tel - Clearwire - Cox - Comcast - Time Warner Cable - Sprint Nextel - US Cellular - MetroPCS - Leap Wireless - T-Mobile - Verizon - Light Squared Uzbekistan - MTS - Ucell (TeliaSonera) Vietnam - VNPT - Indochina Telecom - Viettel For more information visit http://www.researchandmarkets.com/research/kl...lte_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Periodontal Disease - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Those in the Dental Field
M2 - Wed Sep 04, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sp3kl2/periodontal) has announced the addition of the "Periodontal Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Periodontal Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontal Disease, complete with latest updates, and special features on late-stage and discontinued projects. Periodontal Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Periodontal Disease. - A review of the Periodontal Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontal Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aphios Corporation - Biomedical Development Corporation - CSL Limited - Canopus BioPharma Incorporated - Ensoltek Co., Ltd. - Kaken Pharmaceutical Co.,Ltd. - NeoStem, Inc. - Onepharm Research and Development GmbH - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/sp...eriodontal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Acute Coronary Syndrome - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t22wlp/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H2 2013" report to their offering. 'Acute Coronary Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome. Scope - A snapshot of the global therapeutic scenario for Acute Coronary Syndrome. - A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Coronary Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. AstraZeneca PLC GlaxoSmithKline plc Pfizer Inc. Bayer AG Ligand Pharmaceuticals Incorporated Medicure Inc. Arena Pharmaceuticals, Inc. CSL Limited LG Life Sciences, Ltd Auspex Pharmaceuticals Viron Therapeutics, Inc. Regado Biosciences. Cerenis Therapeutics SA Lacer, S.A. Lee's Pharmaceutical Holdings Limited Ampio Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/t2...e_coronary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report: 2013 Profiles 27 Players including Key and Niche Players
M2 - Tue Sep 03, 9:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjhhwq/intravenous#summary) has announced the addition of the "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 27 companies including many key and niche players such as: - Baxter International Inc. - Beijing Tiantan Biological Products Co. Ltd. - Bharat Serums and Vaccines Ltd. - Biotest AG - China Biologic Products Inc. - Guizhou Taibang Biological Products Co. Ltd. - CSL Limited - CSL Behring - Grifols S.A - Huanlan Biological Engineering Inc. - Kedrion S.p.A. - LFB Group - Octapharma AG - OMRIX Biopharmaceuticals Ltd. - Shanghai RAAS Blood Products Co. Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered: Normal 0 false false false MicrosoftInternetExplorer4 I. Introduction, Methodology & Product Definitions Ii. Executive Summary 1. Industry Overview 2. Plasma Proteins - An Overview 3. Immunoglobulins - An Overview 4. Therapy Overview 5. Regulatory Approvals 6. Product Innovations/Introductions 7. Recent Industry Activity 8. Focus On Select Players 9. Global Market Perspective Iii. Market Iv. Competitive Landscape For more information visit http://www.researchandmarkets.com/research/hj...us#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Atherosclerosis - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n99vdc/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2013" report to their offering. 'Atherosclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Atherosclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Atherosclerosis. Scope - A snapshot of the global therapeutic scenario for Atherosclerosis. - A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Atherosclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Isis Pharmaceuticals, Inc. Daiichi Sankyo Company, Ltd Merck & Co., Inc. Novartis AG Dong-A Pharmaceutical Co., Ltd. Dr. Reddy's Laboratories Limited Zydus Cadila Healthcare Limited Bayer AG Genfit PROLOR Biotech, Inc. CSL Limited Yuhan Corporation Anagen Therapeutics, Inc. Cytos Biotechnology AG Pronova BioPharma ASA AFFiRiS AG CIMAB S.A. and many more..... For more information visit http://www.researchandmarkets.com/research/n9...osclerosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Periodontitis - Pipeline Review, H1 2013
M2 - Wed Jul 17, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2qfrh/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H1 2013" report to their offering. 'Periodontitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Periodontitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis prod
